ChungCheng Liu - Adimmune Corp GM Pres

All Insiders Taiwan . 
Stock . Adimmune Corp . Stakeholders . Insider . ChungCheng Liu
4142 Stock  TWD 21.20  0.10  0.47%   

Insider

ChungCheng Liu is GM Pres of Adimmune Corp
Phone886 4 2538 1220
Webhttps://www.adimmune.com.tw

Adimmune Corp Management Efficiency

The company has return on total asset (ROA) of 0.0139 % which means that it generated a profit of $0.0139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0655 %, meaning that it generated $0.0655 on every $100 dollars invested by stockholders. Adimmune Corp's management efficiency ratios could be used to measure how well Adimmune Corp manages its routine affairs as well as how well it operates its assets and liabilities.
Adimmune Corp has accumulated 1.27 B in total debt with debt to equity ratio (D/E) of 206.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Adimmune Corp has a current ratio of 1.31, which is within standard range for the sector. Debt can assist Adimmune Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Adimmune Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Adimmune Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Adimmune to invest in growth at high rates of return. When we think about Adimmune Corp's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

JunBang YeSCI Pharmtech
N/A
ShihShen LeeMedigen Vaccine Biologics
N/A
BS MSScinoPharm Taiwan
N/A
Ricky LiuSCI Pharmtech
N/A
ChungHsin HuangChunghwa Chemical Synthesis
N/A
JunJie LiaoChunghwa Chemical Synthesis
N/A
Michele SeahSCI Pharmtech
N/A
KuanChieh WangChunghwa Chemical Synthesis
N/A
LingHsiao LienScinoPharm Taiwan
N/A
ChaoSheng HongChunghwa Chemical Synthesis
N/A
Deiter YangSCI Pharmtech
N/A
Shun LinScinoPharm Taiwan
N/A
WenChih ChouSCI Pharmtech
N/A
ChihHui LinScinoPharm Taiwan
N/A
LiChiao ChemistryScinoPharm Taiwan
N/A
Jason ChenScinoPharm Taiwan
N/A
Adimmune Corporation manufactures and sells human vaccines in Taiwan. Adimmune Corporation was founded in 1965 and is based in Taichung City, Taiwan. ADIMMUNE CORPORATION operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange. It employs 384 people. Adimmune Corp (4142) is traded on Taiwan Stock Exchange in Taiwan and employs 36 people.

Management Performance

Return On Equity0.0655
Return On Asset0.0139

Adimmune Corp Leadership Team

Elected by the shareholders, the Adimmune Corp's board of directors comprises two types of representatives: Adimmune Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adimmune. The board's role is to monitor Adimmune Corp's management team and ensure that shareholders' interests are well served. Adimmune Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adimmune Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
Fei Pan, Chief Legal Affairs Officer
ChinChuan Chang, COO RD
LiYa Tang, Director Center
ChihHsiang Leng, Head Division
ChungCheng Liu, GM Pres
YinTeng Chang, Chief Officer
MBA MD, Chief Officer
ChiHsien Chan, CEO Chairman

Adimmune Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adimmune Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0655
Return On Asset0.0139
Profit Margin0.21 %
Operating Margin0.08 %
Current Valuation15.44 B
Shares Outstanding421.51 M
Shares Owned By Insiders16.90 %
Shares Owned By Institutions15.86 %
Price To Earning(7.22) X
Price To Book2.47 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Adimmune Stock Analysis

When running Adimmune Corp's price analysis, check to measure Adimmune Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adimmune Corp is operating at the current time. Most of Adimmune Corp's value examination focuses on studying past and present price action to predict the probability of Adimmune Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adimmune Corp's price. Additionally, you may evaluate how the addition of Adimmune Corp to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY